CSL sees first-half profit dip

Blood products group CSL cited foreign exchange losses, falling royalties from a drop in sales of its cervical cancer and swine-flu vaccines for a $117 million dive in first-half profit. The company's net result fell to $500.21 million, down from $617.39 million last year when windfall sales of Panvax, the Australian developed swine flu treatment, boosted its bottom line. News

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.